Today on The Tape Reader: The June CPI report we've been bracing for just delivered a massive downside surprise, instantly rewriting the odds for a July rate hike. But beneath the macro relief, a brutal sector rotation is accelerating—IBM's historic 25% collapse confirms that enterprise budgets are being yanked from traditional software to fund the AI hardware supercycle.
The enterprise rotation from software to AI hardware we've been tracking just claimed a historic casualty. IBM (IBM) shares collapsed by 25% on Tuesday, its worst single-day decline since Black Monday in 1987, after issuing a preliminary Q2 earnings warning. The company reported revenue of $17.2 billion and adjusted EPS of $2.93. CEO Arvind Krishna attributed the shortfall to a sudden shift in enterprise IT spending, with clients diverting budgets away from software and mainframes to secure supply-constrained AI hardware.
Why it matters
IBM's explicit confirmation of capital being cannibalized from software to fund AI hardware purchases provides the ultimate fundamental validation for the sector rotation we've been highlighting. The event creates an immediate short setup in legacy software providers (NOW, ADBE, CSGP also sold off) while reinforcing the long thesis for AI infrastructure and memory names (MU, SKHY, NVDA rallied on the news).
ASML Holdings (ASML) beat Q2 earnings expectations and raised its full-year 2026 revenue outlook for the second time, citing relentless AI-related demand for its lithography equipment. The company now expects net sales of €43 billion to €45 billion, up from a prior range of €36-€40 billion. Q2 net sales were €9.3 billion with a 54% gross margin, both exceeding guidance. The stock surged on the news, breaking out to new highs.
Why it matters
As the monopolistic supplier of EUV lithography machines, ASML's guidance is a critical barometer for the entire semiconductor industry's capital expenditure cycle. This significant guidance raise confirms that the AI infrastructure buildout is not slowing down, providing a strong bullish signal for the entire chip ecosystem. The powerful stock breakout on heavy volume confirms a major episodic pivot, making it a key leadership name to watch.
Aehr Test Systems (AEHR) shares jumped over 23% in extended trading on Tuesday after the company reported blowout fiscal Q4 results. AEHR posted EPS of $0.11, crushing estimates for a one-cent loss. Revenue of $18.84 million also beat expectations. The company announced record quarterly bookings of $60.7 million and issued a fiscal 2027 revenue forecast of $130-$150 million, far exceeding the analyst consensus.
Why it matters
AEHR's report is a textbook earnings gapper setup. The massive beat on both top and bottom lines, combined with record bookings and a powerful forward guidance raise, signals a significant inflection in its business. This makes it a prime candidate for a continuation move at the open, as the results are likely to attract significant institutional sponsorship.
Shares of NextCure (NXTC) surged as much as 314% on Tuesday after the company announced an all-stock merger with privately-held Avere Therapeutics. The deal will combine NextCure's public listing with Avere's oral IL-23 therapy program, AVR-001, which is targeting cancer. The combined company will operate as Avere Therapeutics and trade under the ticker 'AVRX', supported by a concurrent $320 million private placement to fund operations.
Why it matters
This merger is a classic biotech catalyst, providing a lifeline for NextCure while bringing a promising new asset to the public market. The massive stock reaction and simultaneous financing signal strong institutional belief in the new entity's potential. For traders, this creates an extremely volatile parabolic setup with opportunities for both momentum long trades on the initial news and potential fade setups as the initial spike digests.
The FDA has approved Celcuity's (CELC) gedatolisib, to be marketed as Revtorpyk, for adults with HR+/HER2-, PIK3CA wild-type advanced or metastatic breast cancer. This is the first therapy to simultaneously inhibit all class I PI3K isoforms and mTOR. The approval marks Celcuity's transition to a commercial-stage company and caused shares to jump 7% as analysts speculated on its potential as an acquisition target.
Why it matters
Securing a first drug approval is a transformative catalyst for a development-stage biotech, de-risking the company and opening up a significant revenue stream. Revtorpyk's novel mechanism in a large patient population makes Celcuity a more attractive M&A candidate for big pharma looking to bolster oncology pipelines. The stock reaction and buyout speculation create a clear catalyst-driven trading setup.
Technical analysts are highlighting several Indian stocks for potential short-term trades on July 15, based on bullish breakout patterns. JNK India is noted for breaking out of a four-week consolidation with high volume. Route Mobile is showing a breakout from a rounding bottom pattern. Others like JSW Steel, Sun Pharma, and Tata Power are also recommended based on breaking key resistance levels or finding support at important moving averages.
Why it matters
This is a direct feed of scannable, actionable breakout ideas that fit a Stockbee-style momentum framework. Each name is flagged with a specific technical catalyst—a consolidation break, a pattern completion, or a key level reclaim—providing concrete setups for swing traders looking for high relative-strength names with volume confirmation.
SK Hynix (SKHY) American Depositary Receipts (ADRs) are forcefully executing the US-listing valuation catch-up we've been monitoring, surging 27.3% on Tuesday to an all-time high of $193.92. The powerful reversal, which erased its post-IPO slump, was ignited by Barclays initiating coverage with an 'Overweight' rating and a street-high $330 price target. The analyst cited the structural HBM supply-demand imbalance and noted IBM's commentary on accelerating hardware capex as a tailwind.
Why it matters
This event showcases the immense power of a high-conviction analyst call from a tier-1 desk to reverse sentiment and trigger an episodic pivot. For a stock with a thin float and unique trading dynamics like the SK Hynix ADR, this institutional validation acts as a major catalyst. The move also sparked a sympathy rally in other memory names, confirming strong momentum in the AI hardware theme. The wide valuation gap between the ADR and the Seoul-listed shares continues to present a dynamic trading opportunity.
Shares of Arm Holdings (ARM) retreated on Tuesday after HSBC downgraded the stock to 'Hold' from 'Buy', despite raising its price target. HSBC argued that the stock's 122% surge since March has fully priced in its long-term AI growth story. The bank also pointed to a concrete near-term headwind: TSMC's limited 3-nanometer foundry capacity, which could constrain Arm's AI server CPU shipments.
Why it matters
This analyst action is significant because it introduces a rare note of caution into the euphoric AI narrative, backed by a specific, fundamental constraint (foundry capacity). For a high-flying momentum stock like Arm, a downgrade from a major desk on valuation and supply-chain grounds can be a catalyst for a reversal or consolidation, providing a potential short-side setup or a warning to long holders.
Shares of FuelCell Energy (FCEL) saw a surge in trading volume and price on Tuesday after UBS Group upgraded the stock from 'Neutral' to 'Buy'. The firm also raised its price target on the stock to $27.00 from $22.00. The stock rose from a previous close of $19.08 to trade at $21.37.
Why it matters
A rating upgrade from 'Neutral' to 'Buy' by a major firm like UBS can serve as a powerful episodic pivot catalyst. This change in thesis, combined with a significant price target increase, often forces a re-evaluation by the market and can attract new institutional buying, creating a potential breakout setup for swing traders.
Cybersecurity stocks staged a broad rally on Tuesday, with sector leader CrowdStrike (CRWD) surging 11%. The move was largely attributed to a 'risk-on' sentiment that followed the cooler-than-expected June CPI report, which investors interpreted as reducing the likelihood of further Fed rate hikes. Other high-multiple names like Palo Alto Networks and Fortinet also posted strong gains.
Why it matters
This rally demonstrates how macroeconomic data can act as a powerful catalyst for sector-specific flows. For high-growth, high-multiple sectors like cybersecurity, a more dovish Fed outlook is a direct tailwind. The move also dovetails with the narrative from IBM's earnings call, which highlighted cybersecurity as a non-discretionary spending category, suggesting the sector may benefit from both macro relief and fundamental budget reallocation.
U.S. stock futures are pointing to a higher open on Wednesday, extending gains after Tuesday's cooler-than-expected CPI report. S&P 500 futures are testing key resistance levels, with market breadth improving. Traders are now focused on the upcoming Producer Price Index (PPI) release for further inflation clues, as well as Q2 earnings from Morgan Stanley and the Fed's Beige Book.
Why it matters
This provides a tactical read on the market's posture. The follow-through from the CPI rally suggests risk appetite has improved, but key resistance levels and the upcoming PPI catalyst will determine if the move has legs. For intraday positioning, the key levels in SPY/QQQ and the market's reaction to the PPI print at the open will be critical for determining the day's trend.
The critical June CPI report we previewed earlier this week delivered a massive downside surprise. The index registered a 0.4% month-over-month decrease, its largest monthly drop since April 2020, with the annual inflation rate cooling to 3.5%. Critically, the core CPI was flat month-over-month and slowed to 2.6% annually. The cooling was primarily driven by a 9.7% drop in gasoline prices.
Why it matters
This stunningly soft print directly collides with the hawkish dot-plot pivot Fed Chair Warsh signaled in his recent debut, immediately reshaping monetary policy expectations. Fed funds futures show the probability of a July rate hike collapsing from nearly 40% to below 20%. However, the conflict between this retroactive data and the live geopolitical oil price spikes we've been tracking creates a complex setup heading into the PPI report.
Enterprise IT Spend Reallocates from Software to AI Hardware IBM's worst stock decline in 39 years, triggered by an earnings miss, provides stark evidence of a major shift in corporate budgets. CEO Arvind Krishna confirmed clients are diverting capital from software and mainframes to secure supply-constrained servers, memory, and storage for AI buildouts. This has created a clear divergence, punishing software names like Adobe and ServiceNow while boosting hardware players like SK Hynix, Intel, and Nvidia.
Biotech Catalysts Drive M&A and Single-Stock Volatility The biotech sector is a hotbed of activity. Celcuity (CELC) received its first FDA approval for a new breast cancer drug, sparking buyout speculation. NextCure (NXTC) surged over 200% after announcing a merger with Avere Therapeutics to gain access to a promising oral IL-23 therapy. Ligand Pharmaceuticals also completed a major acquisition to expand its royalty portfolio, highlighting the sector's focus on growth through strategic deals and regulatory wins.
Cooler Inflation Print Complicates Fed's Path June's CPI report came in significantly softer than expected, with a 0.4% monthly decline in the headline number and a flat core reading. This data immediately caused traders to slash the odds of a July rate hike. However, Fed Chair Kevin Warsh maintained a hawkish tone, and rising oil prices from geopolitical tensions are keeping future inflation risks on the table, creating a complex and data-dependent environment for markets.
Semiconductor Fortunes Diverge Amid Sector-Wide Rebound While the semiconductor sector is seeing a broad rebound fueled by institutional buying, performance is far from uniform. ASML raised its 2026 forecast on booming AI demand, and SK Hynix's ADRs soared after a street-high price target from Barclays. In contrast, Arm Holdings retreated after an HSBC downgrade cited a rally that has outpaced fundamentals and near-term capacity constraints.
Analyst Calls Act as Key Catalysts for Breakouts and Reversals Tier-1 analyst actions are directly driving significant price moves. HSBC's downgrade of IBM to 'Reduce' amplified its post-earnings collapse. A bullish initiation on SK Hynix from Barclays was the primary catalyst for its 27% surge. Elsewhere, upgrades propelled stocks like FuelCell Energy, while downgrades on names like Apple and Arm triggered immediate selling pressure, creating actionable setups for traders.
What to Expect
2026-07-15—June Producer Price Index (PPI) data to be released, providing another key inflation indicator.
2026-07-15—Fed Beige Book to be released, offering anecdotal insights on economic conditions across Federal Reserve districts.
2026-07-15—Earnings reports expected from Morgan Stanley (MS), BlackRock (BLK), Johnson & Johnson (JNJ), and Cintas (CTAS).
2026-07-28—Start of the two-day FOMC meeting, the second to be chaired by Kevin Warsh.
2026-07-29—FOMC policy decision announcement.
How We Built This Briefing
Every story, researched.
Every story verified across multiple sources before publication.
🔍
Scanned
Across multiple search engines and news databases
646
📖
Read in full
Every article opened, read, and evaluated
206
⭐
Published today
Ranked by importance and verified across sources
12
— The Tape Reader
🎙 Listen as a podcast
Subscribe in your favorite podcast app to get each new briefing delivered automatically as audio.
Apple Podcasts
Library tab → ••• menu → Follow a Show by URL → paste